318 related articles for article (PubMed ID: 29094776)
1. Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy.
Decaussin-Petrucci M; Descotes F; Depaepe L; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Lopez J
Cytopathology; 2017 Dec; 28(6):482-487. PubMed ID: 29094776
[TBL] [Abstract][Full Text] [Related]
2. Cytological features and nuclear scores: Diagnostic tools in preoperative fine needle aspiration of indeterminate thyroid nodules with RAS or BRAF K601E mutations?
Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
Cytopathology; 2021 Jan; 32(1):37-44. PubMed ID: 32803788
[TBL] [Abstract][Full Text] [Related]
3. The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.
Macerola E; Rago T; Proietti A; Basolo F; Vitti P
J Endocrinol Invest; 2019 Feb; 42(2):157-166. PubMed ID: 29704233
[TBL] [Abstract][Full Text] [Related]
4. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
[TBL] [Abstract][Full Text] [Related]
5. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
[TBL] [Abstract][Full Text] [Related]
6. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology.
Johnson SJ; Hardy SA; Roberts C; Bourn D; Mallick U; Perros P
Cytopathology; 2014 Jun; 25(3):146-54. PubMed ID: 24417615
[TBL] [Abstract][Full Text] [Related]
7. Discriminating Interpatient Variabilities of RAS Gene Variants for Precision Detection of Thyroid Cancer.
Fu G; Chazen RS; MacMillan C; Witterick IJ
JAMA Netw Open; 2024 May; 7(5):e2411919. PubMed ID: 38758552
[TBL] [Abstract][Full Text] [Related]
8. Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology?
Yang SE; Sullivan PS; Zhang J; Govind R; Levin MR; Rao JY; Moatamed NA
Cancer Cytopathol; 2016 Feb; 124(2):100-9. PubMed ID: 26422098
[TBL] [Abstract][Full Text] [Related]
9. Laser capture microdissection is a valuable tool in the preoperative molecular screening of follicular lesions of the thyroid: an institutional experience.
Bongiovanni M; Molinari F; Eszlinger M; Paschke R; Barizzi J; Merlo E; Giovanella L; Fasolini F; Cattaneo F; Ramelli F; Mazzucchelli L; Frattini M
Cytopathology; 2015 Oct; 26(5):288-96. PubMed ID: 25487739
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a Two-Year Routine Application of Molecular Testing of Thyroid Fine-Needle Aspirations Using a Seven-Gene Panel in a Primary Referral Setting in Germany.
Eszlinger M; Böhme K; Ullmann M; Görke F; Siebolts U; Neumann A; Franzius C; Adam S; Molwitz T; Landvogt C; Amro B; Hach A; Feldmann B; Graf D; Wefer A; Niemann R; Bullmann C; Klaushenke G; Santen R; Tönshoff G; Ivancevic V; Kögler A; Bell E; Lorenz B; Kluge G; Hartenstein C; Ruschenburg I; Paschke R
Thyroid; 2017 Mar; 27(3):402-411. PubMed ID: 28071986
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy.
Bellevicine C; Migliatico I; Sgariglia R; Nacchio M; Vigliar E; Pisapia P; Iaccarino A; Bruzzese D; Fonderico F; Salvatore D; Biondi B; Masone S; Novizio V; Scavuzzo F; Serino D; De Palma M; Chiofalo MG; Botti G; Pezzullo L; Nuzzo V; Spiezia S; De Chiara G; Iorio S; Conzo G; Docimo G; Faggiano A; Bongiovanni M; Malapelle U; Colao A; Triassi M; Troncone G;
Cancer Cytopathol; 2020 Feb; 128(2):107-118. PubMed ID: 31821746
[TBL] [Abstract][Full Text] [Related]
13. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
14. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates.
Marchetti I; Lessi F; Mazzanti CM; Bertacca G; Elisei R; Coscio GD; Pinchera A; Bevilacqua G
Thyroid; 2009 Aug; 19(8):837-42. PubMed ID: 19534623
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of residual ThinPrep material from thyroid FNAs increases diagnostic sensitivity.
Krane JF; Cibas ES; Alexander EK; Paschke R; Eszlinger M
Cancer Cytopathol; 2015 Jun; 123(6):356-61. PubMed ID: 25926393
[TBL] [Abstract][Full Text] [Related]
16. Semiquantitative assessment of cytomorphologic features can predict mutation status of thyroid nodules with indeterminate cytologic diagnosis.
Shahi M; Bloechl SJ; Vogel RI; Shrestha R; Krigman HR; Evasovich M; Burmeister LA; Amin K
Hum Pathol; 2019 Nov; 93():81-89. PubMed ID: 31437520
[TBL] [Abstract][Full Text] [Related]
17. Malignant risk stratification of thyroid FNA specimens with indeterminate cytology based on molecular testing.
Paskaš S; Janković J; Živaljević V; Tatić S; Božić V; Nikolić A; Radojković D; Savin S; Cvejić D
Cancer Cytopathol; 2015 Aug; 123(8):471-9. PubMed ID: 25924719
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600 co-testing is technically feasible in conventional thyroid fine needle aspiration (FNA) cytology smears and can reduce the need for completion thyroidectomy.
Poller DN; Glaysher S
Cytopathology; 2014 Jun; 25(3):155-9. PubMed ID: 24164374
[TBL] [Abstract][Full Text] [Related]
20. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
Hyeon J; Ahn S; Shin JH; Oh YL
Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
